Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
October 23, 2013
Human genome-guided identification of memory-modulating drugs
Andreas Papassotiropoulos, Christiane Gerhards, Angela Heck, et al.
Brain Communications
|
November 29, 2023
Targeting amyotrophic lateral sclerosis by neutralizing seeding-competent TDP-43 in CSF
Mickael Audrain, Anne-Laure Egesipe, Noémie Tentillier, et al.
Cell Reports
|
August 1, 2016
Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement
Seung-Hye Lee, Claire E Le Pichon, Oskar Adolfsson, et al.
JAMA Neurology
|
May 9, 2022
Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial
Michael S Rafii, Olivier Sol, William C Mobley, et al.
Neurobiology of Disease
|
February 22, 2023
Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD
Tariq Afroz, Elodie Chevalier, Mickael Audrain, et al.
Nature Communications
|
October 27, 2023
The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases
Ruben Smith, Francesca Capotosti, Martin Schain, et al.
Nature Communications
|
October 24, 2025
Development of [<sup>18</sup>F]ACI-19626 as a first-in-class brain PET tracer for imaging TDP-43 pathology
Efthymia Vokali, Elodie Chevalier, Nicolas Dreyfus, et al.
Plos One
|
March 30, 2016
An Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome
Pavel V Belichenko, Rime Madani, Lorianne Rey-Bellet, et al.
Plos One
|
May 12, 2025
Correction: An Anti-β-Amyloid vaccine for treating cognitive deficits in a mouse model of down syndrome
Pavel V Belichenko, Rime Madani, Lorianne Rey-Bellet, et al.
Ebiomedicine
|
September 19, 2025
Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled study
Olivier Sol, Julien Mermoud, Merja Hallikainen, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
Proceedings of the National Academy of Sciences of the United States of America
|
October 23, 2013
Human genome-guided identification of memory-modulating drugs
Andreas Papassotiropoulos, Christiane Gerhards, Angela Heck, et al.
Brain Communications
|
November 29, 2023
Targeting amyotrophic lateral sclerosis by neutralizing seeding-competent TDP-43 in CSF
Mickael Audrain, Anne-Laure Egesipe, Noémie Tentillier, et al.
Cell Reports
|
August 1, 2016
Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement
Seung-Hye Lee, Claire E Le Pichon, Oskar Adolfsson, et al.
JAMA Neurology
|
May 9, 2022
Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial
Michael S Rafii, Olivier Sol, William C Mobley, et al.
Neurobiology of Disease
|
February 22, 2023
Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD
Tariq Afroz, Elodie Chevalier, Mickael Audrain, et al.
Nature Communications
|
October 27, 2023
The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases
Ruben Smith, Francesca Capotosti, Martin Schain, et al.
Nature Communications
|
October 24, 2025
Development of [<sup>18</sup>F]ACI-19626 as a first-in-class brain PET tracer for imaging TDP-43 pathology
Efthymia Vokali, Elodie Chevalier, Nicolas Dreyfus, et al.
Plos One
|
March 30, 2016
An Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome
Pavel V Belichenko, Rime Madani, Lorianne Rey-Bellet, et al.
Plos One
|
May 12, 2025
Correction: An Anti-β-Amyloid vaccine for treating cognitive deficits in a mouse model of down syndrome
Pavel V Belichenko, Rime Madani, Lorianne Rey-Bellet, et al.
Ebiomedicine
|
September 19, 2025
Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled study
Olivier Sol, Julien Mermoud, Merja Hallikainen, et al.
Page
of 6